Generic Wegovy Is Here: Sevmia Approved in Canada
On June 29, 2026, Health Canada approved Sevmia (Apotex) - the first generic version of Wegovy (semaglutide) for chronic weight management, and the first generic semaglutide approved for weight loss in Canada. Here is what Sevmia is, who it is for, what it is likely to cost, and how it fits the wider generic semaglutide rollout.
Latest update - June 30, 2026
Health Canada approved Sevmia (Apotex) on June 29, 2026 - the first generic Wegovy and the first generic semaglutide cleared for weight management in Canada. Pricing has not been published yet; see the outlook below.
Last updated: June 30, 2026.
Generic Wegovy in Canada: What Sevmia Is
On June 29, 2026, Health Canada authorized Sevmia - a generic semaglutide made by Apotex, developed with Orbicular Pharmaceutical Technologies. It is the first generic version of Wegovy and the first generic semaglutide approved in Canada for chronic weight management. Sevmia references Wegovy (Novo Nordisk) as its brand comparator. Most news outlets reported the product as “Svemia,” a transposition; Apotex and Health Canada spell it Sevmia.
Health Canada authorized Sevmia for chronic weight management in patients aged 12 and older, as an adjunct to a reduced-calorie diet and increased physical activity, for adults with obesity (BMI of 30 or higher) or overweight (BMI of 27 or higher) with at least one weight-related comorbidity, and to reduce the risk of a non-fatal heart attack in adults with established cardiovascular disease and a BMI of 27 or higher. Sevmia is a once-weekly injection. Follow the dosing set out in the official Sevmia product monograph and confirm it with your prescriber or pharmacist.
Sevmia is the third generic semaglutide cleared in Canada, but the first for weight loss. The earlier two - Dr. Reddy's (April 28, 2026) and Apotex's Apo-Semaglutide Injection (May 1, 2026) - reference Ozempic and cover the type 2 diabetes indication only. Health Canada is reviewing six other generic semaglutide submissions, with more decisions expected in the coming weeks and months.
Brand comparator
Wegovy (Novo Nordisk)
Manufacturer
Apotex, with Orbicular Pharmaceutical Technologies
Approved
June 29, 2026 by Health Canada
Indication
Chronic weight management, ages 12+
Dosing
Once-weekly injection
Status
Third generic semaglutide, first for weight loss
Approval Timeline
Based on publicly available Health Canada filings and regulatory timelines. This timeline is built from public information only - we do not have advance knowledge of Health Canada decisions.
October 30, 2025
Dr. Reddy's Laboratories received a Notice of Non-Compliance from Health Canada on its initial generic semaglutide submission (resolved - see April 28, 2026).
December 22, 2025
Health Canada approved Plosbrio and Poviztra, Novo Nordisk's lower-cost authorized brands of Ozempic and Wegovy respectively, ahead of the expected generic wave.
January 4, 2026
Novo Nordisk's semaglutide data exclusivity expired in Canada, opening the regulatory pathway for generic manufacturers.
January 2026
Seven generic semaglutide submissions under Health Canada review from Sandoz Canada, Apotex (three submissions), Taro Pharmaceuticals, Aspen Pharmacare, and Teva Canada.
February 2, 2026
PharmaTher announced a strategic initiative to pursue Health Canada approval for generic semaglutide, targeting broad dose coverage from 0.25 mg to 2.4 mg.
April 28, 2026
Dr. Reddy's Laboratories approved - the first generic semaglutide approved by Health Canada. Type 2 diabetes indication only (equivalent to generic Ozempic). Dr. Reddy's resolved its October 2025 Notice of Non-Compliance in about six months.
May 1, 2026
Apotex approved - Health Canada authorized Apo-Semaglutide Injection, the second generic semaglutide product in Canada. Type 2 diabetes indication only.
June 29, 2026
Sevmia (Apotex) approved - the first generic semaglutide authorized by Health Canada for chronic weight management, and the first generic referencing Wegovy rather than Ozempic. Developed by Apotex with Orbicular Pharmaceutical Technologies. Most news outlets reported the name as “Svemia,” a transposition; Apotex and Health Canada spell it “Sevmia.”
Through 2026
Six additional generic semaglutide submissions remain under Health Canada review. Further decisions are expected in the coming weeks and months. Manufacturer production scale-up and pharmacy availability typically lag approval by weeks to months.
Find out if you qualify for GLP-1 treatment
Licensed Canadian providers review your eligibility in minutes - no clinic visit needed.
What the Price Drop Will Actually Look Like
Canada's generic drug pricing framework - the pan-Canadian Tiered Pricing Framework, administered through the pan-Canadian Pharmaceutical Alliance - caps generic prices in steps as more manufacturers enter a market, with an automatic step-down built in even at the single-generic stage.
Using the current manufacturer list price for Ozempic of roughly $228 for a four-week supply (the official brand reference price, before pharmacy and distributor markups), the framework caps generic prices as follows:
| Stage | Generic price cap | Reduction from brand list |
|---|---|---|
| 1 generic, first 3 months | 75% of brand (~$171) | ~25% off |
| 1 generic, after 3 months | 55% of brand (~$125) | ~45% off |
| 2 generics | 50% of brand (~$114) | ~50% off |
| 3 or more generics (injectables) | 35% of brand (~$80) | ~65% off |
These are list-price caps for public drug plan formularies. Retail prices include pharmacy dispensing fees and markups, so absolute dollar figures at the counter will be higher than the table, but the percentage reductions track proportionally.
With three generic semaglutide products now approved (the latest, Sevmia, on June 29, 2026) and pharmacy launches just beginning, the realistic near-term consumer price reduction lands in the 25 to 50 percent range, depending on which generics are actively dispensing in your province. The 65 percent figure is the floor reached only after three or more manufacturers are simultaneously on market.
What Will Sevmia Cost? (Pricing Pending)
No Sevmia price has been published yet. Health Canada notes that generic medicines are typically 45 to 90 percent cheaper than the brand once competition builds, so generic Wegovy pricing should land well below brand Wegovy over time - but the exact launch price, provinces, and pharmacies are not yet confirmed. The tiered-pricing framework above shows how those reductions typically phase in as more manufacturers enter the market.
Availability & pricing pending
We will update this page with verified Sevmia prices, provinces, and pharmacies the moment they are announced. Check back, or read our generic semaglutide guide for the wider rollout.
Asking for a Generic Substitution
If your prescription is written for Wegovy, ask your pharmacist or prescriber whether a generic substitution with Sevmia is available once it is stocked in your province. Telehealth providers in Canada can also confirm which brand your prescription is written for if you are unsure.
Substitution rules vary by province and by drug plan, and interchangeability for injectable pens is not automatic in every jurisdiction, so confirm with your pharmacist before assuming a switch will be filled. Your weekly dosing schedule should not change when moving between the same semaglutide strengths, but confirm the titration step with your prescriber.
More Generics Are Coming
Sevmia is unlikely to be the last word. Six additional generic semaglutide submissions remain under Health Canada review, with further decisions expected in the coming weeks and months. Each new approval moves the market down another rung of the tiered-pricing framework, and manufacturer production scale-up and pharmacy availability typically lag approval by weeks to months.
The direction of travel is clear: semaglutide for weight management is shifting from a premium branded product toward the competitive pricing typical of a mature generic market. Sevmia is the first generic Wegovy to cross that line in Canada.
Sources
- Health Canada - Canada approves first generic semaglutide for weight loss
- Apotex press release (PR Newswire) - Health Canada approval for Sevmia
- CBC - Apotex generic Wegovy approval
- CTV News - Health Canada approves first generic semaglutide for weight loss
- Global News - Canada semaglutide injection for weight loss